In an early trial, a one-time gene-editing therapy (VERVE-102) reduced “bad” LDL cholesterol by up to 62% in high-risk patients, with…

Закрепи.sender (@heartysender), Jun 13, 2026, 09:40 UTC

In an early trial, a one-time gene-editing therapy (VERVE-102) reduced “bad” LDL cholesterol by up to 62% in high-risk patients, with effects lasting up to 18 months and no serious safety concerns. By permanently switching off the PCSK9 gene in the liver, the treatment could offer a long-term alternative to daily cholesterol-lowering medications. https://www.nejm.org/doi/10.1056/NEJMoa2601283

The excerpt is quoted from a public Telegram channel, which owns its text.

Read the original post on Telegram

More posts from Закрепи.sender · All channels